NCT05327881

Brief Summary

Whole blood lactate concentration is widely used in shock states to assess perfusion. We aimed to determine if the change in plasma renin concentration over time would be superior to the change in lactate concentration for predicting in-hospital mortality in septic shock patients.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jun 2022

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 16, 2022

Completed
29 days until next milestone

First Posted

Study publicly available on registry

April 14, 2022

Completed
3 months until next milestone

Study Start

First participant enrolled

June 30, 2022

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2023

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2023

Completed
Last Updated

April 14, 2022

Status Verified

April 1, 2022

Enrollment Period

1 year

First QC Date

March 16, 2022

Last Update Submit

April 7, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change in Plasma renin levels at enrollment and after 24, 48, and 72 hours in septic shock patients

    At enrollment and after 24, 48, and 72 hours.

Secondary Outcomes (1)

  • 28 days mortality

    28 days

Study Arms (1)

Septic shock patients

Adult patients on vasopressors for greater than 6 hours to maintain a mean arterial pressure greater than or equal to 65 mm Hg. Inclusion criteria: age over 18, urinary catheter in situ, anticipated stay \>24 hours, and signed informed consent by patient or next-of-kin. Septic shock was defined as persistent hypotension (defined as the need for vasopressors to maintain mean arterial pressure ≥ 65 mm Hg, and a serum lactate level \> 18 mg/dL \[2 mmol/L\] despite adequate volume resuscitation

Diagnostic Test: Plasma renin concentrations will be measured at enrollment and at 24, 48, and 72 hours. Whole blood lactate measurements will be performed according to normal standard of care.

Interventions

Measurement of Whole Blood Lactate Concentrations: Whole blood lactate concentrations were measured using ABL 800 series analyzers. The IRB (Institutional Review Board) protocol specified that lactate concentrations could be obtained as part of routine care, but lactate concentrations were not measured independently for research purposes. Measurement of Plasma Renin Concentrations: Discarded whole blood samples (waste blood samples) in EDTA (ethylenediaminetetraacetic acid) (BD Vacutainer, 4 mL) tubes were prospectively collected from each patient at the time of study enrollment and at 24, 48, and 72 hours. Plasma active renin levels were measured using the active renin enzyme-linked immunosorbent assay kit (DRG International, Township, NJ)

Septic shock patients

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Septic shock patients, septic shock was defined as persistent hypotension (defined as the need for vasopressors to maintain mean arterial pressure ≥ 65 mm Hg, and a serum lactate level \> 18 mg/dL \[2 mmol/L\] despite adequate volume resuscitation

You may qualify if:

  • age over 18
  • anticipated stay \>24 hours
  • signed informed consent by patient or next-of-kin.
  • Septic shock patients, septic shock was defined as persistent hypotension (defined as the need for vasopressors to maintain mean arterial pressure ≥ 65 mm Hg, and a serum lactate level \> 18 mg/dL \[2 mmol/L\] despite adequate volume resuscitation

You may not qualify if:

  • chronic kidney disease stage IV/V (baseline eGFR (estimated glomerular filtration rate) \<30ml/min/1.73m2),
  • do not resuscitate order.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Shock, Septic

Condition Hierarchy (Ancestors)

SepsisInfectionsSystemic Inflammatory Response SyndromeInflammationPathologic ProcessesPathological Conditions, Signs and SymptomsShock

Study Officials

  • Khaled A. AbdelRahman, Assistant professor

    Assiut University

    STUDY CHAIR
  • Nagwa M. Ibrahim, Professor

    Assiut University

    STUDY CHAIR
  • Abualauon M. Abedalmohsen, Lecturer

    Assiut University

    STUDY CHAIR

Central Study Contacts

Omar Rabiee, masters degree

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Lecturer, Anesthesia and ICU department, Faculty of medicine, Assiut University

Study Record Dates

First Submitted

March 16, 2022

First Posted

April 14, 2022

Study Start

June 30, 2022

Primary Completion

June 30, 2023

Study Completion

December 30, 2023

Last Updated

April 14, 2022

Record last verified: 2022-04